Literature DB >> 24003284

Severe refractory atopic dermatitis in an adolescent patient successfully treated with ustekinumab.

Anna Agusti-Mejias1, Francesc Messeguer, Ramón García, Isabel Febrer.   

Abstract

Entities:  

Year:  2013        PMID： 24003284      PMCID： PMC3756206          DOI： 10.5021/ad.2013.25.3.368

Source DB:  PubMed          Journal:  Ann Dermatol        ISSN： 1013-9087            Impact factor:   1.444


× No keyword cloud information.
  5 in total

1.  Treatment of severe refractory adult atopic dermatitis with ustekinumab.

Authors:  Rafael Puya; Maria Alvarez-López; Antonio Velez; Enrique Casas Asuncion; José Carlos Moreno
Journal:  Int J Dermatol       Date:  2012-01       Impact factor: 2.736

2.  Decrease in circulating Th17 cells correlates with increased levels of CCL17, IgE and eosinophils in atopic dermatitis.

Authors:  Sayaka Hayashida; Hiroshi Uchi; Yoichi Moroi; Masutaka Furue
Journal:  J Dermatol Sci       Date:  2010-11-03       Impact factor: 4.563

Review 3.  The IL-17 pathway as a major therapeutic target in autoimmune diseases.

Authors:  Yan Hu; Fang Shen; Natasha K Crellin; Wenjun Ouyang
Journal:  Ann N Y Acad Sci       Date:  2010-12-13       Impact factor: 5.691

Review 4.  The IL-23/Th17 axis in the immunopathogenesis of psoriasis.

Authors:  Antonella Di Cesare; Paola Di Meglio; Frank O Nestle
Journal:  J Invest Dermatol       Date:  2009-03-26       Impact factor: 8.551

5.  Possible pathogenic role of Th17 cells for atopic dermatitis.

Authors:  Chizuko Koga; Kenji Kabashima; Noriko Shiraishi; Miwa Kobayashi; Yoshiki Tokura
Journal:  J Invest Dermatol       Date:  2008-04-24       Impact factor: 8.551
  5 in total
  9 in total

Review 1.  Monoclonal antibodies: the new magic bullets for allergy: IUPHAR Review 17.

Authors:  N Landolina; F Levi-Schaffer
Journal:  Br J Pharmacol       Date:  2016-02-01       Impact factor: 8.739

2.  Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis.

Authors:  Saakshi Khattri; Patrick M Brunner; Sandra Garcet; Robert Finney; Steven R Cohen; Margeaux Oliva; Riana Dutt; Judilyn Fuentes-Duculan; Xiuzhong Zheng; Xuan Li; Kathleen M Bonifacio; Norma Kunjravia; Israel Coats; Inna Cueto; Patricia Gilleaudeau; Mary Sullivan-Whalen; Mayte Suárez-Fariñas; James G Krueger; Emma Guttman-Yassky
Journal:  Exp Dermatol       Date:  2016-08-09       Impact factor: 3.960

Review 3.  Novel Biologicals for the Treatment of Allergic Diseases and Asthma.

Authors:  Hern-Tze Tina Tan; Kazunari Sugita; Cezmi A Akdis
Journal:  Curr Allergy Asthma Rep       Date:  2016-10       Impact factor: 4.806

Review 4.  [New aspects in systemic treatment of atopic dermatitis].

Authors:  T Werfel; A Wollenberg; T Pumnea; A Heratizadeh
Journal:  Hautarzt       Date:  2018-03       Impact factor: 0.751

5.  Multiple Lentigines Arising in Sites of Resolving Psoriatic Plaques after Treatment with Ustekinumab.

Authors:  Jeong Soo Kim; Seul Ki Lee; Ha Ryeong Ryu; Chul Hyun Yun; Jin Ok Baek; Joo Young Roh; Jong Rok Lee
Journal:  Ann Dermatol       Date:  2018-04-23       Impact factor: 1.444

Review 6.  Alternative uses of ustekinumab for non-indicated dermatological conditions: a systematic review.

Authors:  Sahil Rawal; Sara Kianian; William Guo; Jocellie Marquez; Marissa Ayasse; Katherine A Siamas; Yoojin Lee; Joann Salvemini
Journal:  Arch Dermatol Res       Date:  2021-06-22       Impact factor: 3.017

Review 7.  Biological Treatments in Atopic Dermatitis.

Authors:  Andrea Montes-Torres; Mar Llamas-Velasco; Alejandra Pérez-Plaza; Guillermo Solano-López; Javier Sánchez-Pérez
Journal:  J Clin Med       Date:  2015-04-03       Impact factor: 4.241

8.  A human and animal model-based approach to investigating the anti-inflammatory profile and potential of the 5-HT2B receptor antagonist AM1030.

Authors:  Niklas Palmqvist; Max Siller; Cecilia Klint; Anders Sjödin
Journal:  J Inflamm (Lond)       Date:  2016-06-22       Impact factor: 4.981

9.  Erythrodermic Psoriasis Improved by Ustekinumab: A Report of Two Cases.

Authors:  Ye Seul Kim; Hyun Ju Kim; Sanghoon Lee; Young Lip Park
Journal:  Ann Dermatol       Date:  2016-01-28       Impact factor: 1.444
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.